Evidence map›Paper›PMID 32323287›Full record

ArticlePneumologie (Stuttgart, Germany)2020

[Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].

M Pfeifer, S Ewig, T Voshaar, W Randerath, T Bauer, J Geiseler, D Dellweg, M Westhoff, W Windisch, B Schönhofer and 2 more

Open access · bronzeAbstract readConsensus Statement
In one paragraph

Article in Pneumologie (Stuttgart, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Early versus late tracheostomy in critically ill COVID-19 patients.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Guideline
  3. Guideline
  4. High-flow nasal cannulaTherapeutic advances in respiratory disease
    Pooled it
  5. Article
  6. Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19.Respiration; international review of thoracic diseases · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. ELMO, a new helmet interface for CPAP to treat COVID-19-related acute hypoxemic respiratory failure outside the ICU: a feasibility study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022
    Article
  13. Review
  14. Review
  15. Observational
  16. Review
  17. Article
  18. Article
  19. [Weaning in a Pandemic Situation - A Position Paper].Pneumologie (Stuttgart, Germany) · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 2 countries.

M PfeiferKlinik und Poliklinik für Innere Medizin II, Universitätsklinik Regensburg, Regensburg.
S EwigThoraxzentrum Ruhrgebiet, Department of Respiratory and Infectious Diseases, EVK Herne and Augusta-Krankenanstalt Bochum, Bochum.
T VoshaarSchwerpunkt Pneumologie, Allergologie, Klinische Immunologie, Zentrum für Schlaf- und Beatmungsmedizin, Krankenhaus Bethanien, Moers.
W RanderathInstitut für Pneumologie an der Universität zu Köln, Köln.
T BauerLungenklinik Heckeshorn, Helios Klinikum Emil von Behring GmbH, Berlin.
J GeiselerMedizinische Klinik IV: Klinik für Pneumologie, Beatmungs- und Schlafmedizin, Klinikum Vest GmbH, Paracelsus-Klinik, Marl.
D DellwegFachkrankenhaus Kloster Grafschaft GmbH, Akademisches Lehrkrankenhaus der Philipps-Universität Marburg, Schmallenberg Grafschaft.
M WesthoffKlinik für Pneumologie, Lungenklinik Hemer, Hemer.
W WindischUniversität Witten-Herdecke, Witten.
B SchönhoferPneumologische Praxis und pneumologischer Konsildienst im Klinikum Agnes Karll Laatzen, Klinikum Region Hannover, Laatzen.
S KlugeKlinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
P M LepperInnere Medizin V - Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar.
Krankenhaus Bethanien · DEAugusta-Kranken-Anstalt · DEFachkrankenhaus Kloster Grafschaft · DEHelios Klinikum Emil von Behring · DEKlinikum Region Hannover · DEKlinikum Vest · DEKrankenhaus Barmherzige Brüder · DELungenklinik Hemer · DEUniversitätsklinikum des Saarlandes · DEUniversity Medical Center Hamburg-Eppendorf · DEWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Against the background of the pandemic caused by infection with the SARS-CoV-2, the German Society for Pneumology and Respiratory Medicine (DGP e.V.), in cooperation with other associations, has designated a team of experts in order to answer the currently pressing questions about therapy strategies in dealing with COVID-19 patients suffering from acute respiratory insufficiency (ARI).The position paper is based on the current knowledge that is evolving daily. Many of the published and cited studies require further review, also because many of them did not undergo standard review processes.Therefore, this position paper is also subject to a continuous review process and will be further developed in cooperation with the other professional societies.This position paper is structured into the following five topics:1. Pathophysiology of acute respiratory insufficiency in patients without immunity infected with SARS-CoV-22. Temporal course and prognosis of acute respiratory insufficiency during the course of the disease3. Oxygen insufflation, high-flow oxygen, non-invasive ventilation and invasive ventilation with special consideration of infectious aerosol formation4. Non-invasive ventilation in ARI5. Supply continuum for the treatment of ARIKey points have been highlighted as core statements and significant observations. Regarding the pathophysiological aspects of acute respiratory insufficiency (ARI), the pulmonary infection with SARS-CoV-2 COVID-19 runs through three phases: early infection, pulmonary manifestation and severe hyperinflammatory phase.There are differences between advanced COVID-19-induced lung damage and those changes seen in Acute Respiratory Distress Syndromes (ARDS) as defined by the Berlin criteria. In a pathophysiologically plausible - but currently not yet histopathologically substantiated - model, two types (L-type and H-type) are distinguished, which correspond to an early and late phase. This distinction can be taken into consideration in the differential instrumentation in the therapy of ARI.The assessment of the extent of ARI should be carried out by an arterial or capillary blood gas analysis under room air conditions and must include the calculation of the oxygen supply (measured from the variables of oxygen saturation, the Hb value, the corrected values of the Hüfner number and the cardiac output). In principle, aerosols can cause transmission of infectious viral particles. Open systems or leakage systems (so-called vented masks) can prevent the release of respirable particles. Procedures in which the invasive ventilation system must be opened, and endotracheal intubation must be carried out are associated with an increased risk of infection.The protection of personnel with personal protective equipment should have very high priority because fear of contagion must not be a primary reason for intubation. If the specifications for protective equipment (eye protection, FFP2 or FFP-3 mask, gown) are adhered to, inhalation therapy, nasal high-flow (NHF) therapy, CPAP therapy or NIV can be carried out according to the current state of knowledge without increased risk of infection to the staff. A significant proportion of patients with respiratory failure presents with relevant hypoxemia, often also caused by a high inspiratory oxygen fraction (FiO2) including NHF, and this hypoxemia cannot be not completely corrected. In this situation, CPAP/NIV therapy can be administered under use of a mouth and nose mask or a respiratory helmet as therapy escalation, as long as the criteria for endotracheal intubation are not fulfilled.In acute hypoxemic respiratory insufficiency, NIV should be performed in an intensive care unit or in a comparable unit by personnel with appropriate expertise. Under CPAP/NIV, a patient can deteriorate rapidly. For this reason, continuous monitoring with readiness to carry out intubation must be ensured at all times. If CPAP/NIV leads to further progression of ARI, intubation and subsequent invasive ventilation should be carried out without delay if no DNI order is in place.In the case of patients in whom invasive ventilation, after exhausting all guideline-based measures, is not sufficient, extracorporeal membrane oxygenation procedure (ECMO) should be considered to ensure sufficient oxygen supply and to remove CO

Indexed as

Continuous Positive Airway PressurePositive-Pressure RespirationPractice Guidelines as TopicBerlinBetacoronavirusCoronavirus InfectionsCOVID-19HumansIntubation, IntratrachealLungNoninvasive VentilationPandemicsPneumonia, ViralPulmonary EdemaRespiratory Distress SyndromeRespiratory Insufficiency

Identifiers

PMID32323287
PMCPMC7378547
OpenAlexW3025128128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.